- Home
- PAYC vs NBIX Comparison
PAYC vs NBIX Comparison
Compare PAYC & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYC
- NBIX
- Stock Information
- Founded
- PAYC 1998
- NBIX 1992
- Country
- PAYC United States
- NBIX United States
- Employees
- PAYC N/A
- NBIX N/A
- Industry
- PAYC Computer Software: Prepackaged Software
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAYC Technology
- NBIX Health Care
- Exchange
- PAYC Nasdaq
- NBIX Nasdaq
- Market Cap
- PAYC 14.6B
- NBIX 12.0B
- IPO Year
- PAYC 2014
- NBIX 1996
- Fundamental
- Price
- PAYC $259.11
- NBIX $123.02
- Analyst Decision
- PAYC Hold
- NBIX Strong Buy
- Analyst Count
- PAYC 11
- NBIX 20
- Target Price
- PAYC $230.00
- NBIX $163.20
- AVG Volume (30 Days)
- PAYC 600.5K
- NBIX 1.6M
- Earning Date
- PAYC 05-07-2025
- NBIX 05-05-2025
- Dividend Yield
- PAYC 0.58%
- NBIX N/A
- EPS Growth
- PAYC N/A
- NBIX N/A
- EPS
- PAYC 7.02
- NBIX 2.96
- Revenue
- PAYC $1,913,800,000.00
- NBIX $2,412,600,000.00
- Revenue This Year
- PAYC $9.97
- NBIX $15.99
- Revenue Next Year
- PAYC $9.27
- NBIX $14.93
- P/E Ratio
- PAYC $36.92
- NBIX $41.60
- Revenue Growth
- PAYC 9.87
- NBIX 21.73
- 52 Week Low
- PAYC $139.50
- NBIX $84.23
- 52 Week High
- PAYC $262.80
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- PAYC 63.57
- NBIX 62.85
- Support Level
- PAYC $253.44
- NBIX $117.59
- Resistance Level
- PAYC $262.66
- NBIX $125.63
- Average True Range (ATR)
- PAYC 5.61
- NBIX 2.98
- MACD
- PAYC -0.95
- NBIX -0.02
- Stochastic Oscillator
- PAYC 66.82
- NBIX 72.90
About PAYC Paycom Software Inc.
Founded in 1998, Paycom is a human capital management software-as-a-service provider addressing customer requirements surrounding payroll, talent acquisition, talent management, HR management, as well as time and labor. The company primarily services midsize businesses within the United States, targeting businesses with 50-10,000 employees. The company primarily generates revenue through the sale of subscriptions providing access to its HCM platform. To a lesser extent, the company also generates revenue from implementation services provided to customers as well as interest income generated from customer funds. As of fiscal 2024, the company serviced slightly over 37,500 customers and stored data on over 7 million employees.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.